Join
Live feed
·
PRReleasevia Quantisnow
MiNK Therapeutics Inc. logo

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

ByQuantisnow·Wall Street's wire, on your screen.
INKT· MiNK Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INKT (MiNK Therapeutics Inc.) and more on Quantisnow.